文献速递膀胱癌与上尿路尿路上皮癌

原发性T1高级别非肌层浸润性膀胱癌患者的进展风险——一项当代队列研究

Risk of progression in patients with primary T1 high grade non-muscle invasive bladder cancer - a contemporary cohort.
PubMed 文献 · Eur Urol Oncol · 2024-09-25

本研究纳入1268例接受至少一次卡介苗(BCG)灌注并至少进行一次膀胱镜评估的原发性高级别/3级(HG/G3)T1非肌层浸润性膀胱癌(NMIBC)患者,评估1年进展风险。全部患者1年进展风险为6.5%(95%CI 5.2-8.0),接受充分BCG治疗(n=746)的患者自第二疗程首次灌注后1年进展风险为4.6%(95%CI 3.3-6.4)。结论认为当代接受BCG治疗的患者进展风险似乎较低,尤其是接受充分BCG治疗者。

要点

  • 原发性HG/G3 T1 NMIBC患者开始BCG治疗后1年进展风险为6.5%(95%CI 5.2-8.0)。
  • 接受充分BCG治疗(n=746)的患者第二疗程首次灌注后1年进展风险为4.6%(95%CI 3.3-6.4)。
  • 充分BCG定义为至少5次诱导灌注且6个月内第二疗程至少2次灌注。

核心结论

  • 当代接受BCG治疗的HG/G3 T1 NMIBC患者进展风险似乎较低,尤其是接受充分BCG治疗者。

研究设计与样本

  • 当代队列研究,纳入1268例接受至少一次BCG灌注并至少进行一次膀胱镜评估的原发性HG/G3 T1 NMIBC患者。

主要发现

  • 全部患者开始BCG治疗后1年进展风险为6.5%(95%CI 5.2-8.0)。
  • 接受充分BCG治疗的患者(n=746)自第二疗程首次灌注后1年进展风险为4.6%(95%CI 3.3-6.4)。

关键数值与推荐

  • 充分BCG定义为至少5次诱导灌注且6个月内第二疗程至少提供2次灌注。
  • 进展定义为逼尿肌浸润或淋巴结转移或远处转移。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with high-risk non-muscle-invasive bladder cancer (NMIBC) receive bacillus Calmette-Guérin (BCG) instillations to reduce the risk of progression. For patients with very high-risk NMIBC, immediate radical cystectomy may be considered, as patients who experience disease progression despite BCG treatment have a worse prognosis. However, guideline-recommended stratification for the risk of progression is based on data from patients who were not exposed to BCG. We evaluated the risk of progression in a contemporary cohort of patients with primary high-grade/grade 3 (HG/G3) T1 NMIBC (n = 1268) who received at least one BCG instillation and underwent at least one cystoscopic evaluation. The primary endpoint was the 1-yr risk of progression for all patients and for the subgroup that received adequate BCG, defined as at least five induction instillations and at least two instillations provided as a second BCG course within 6 mo. Progression was defined as detrusor muscle invasion or lymph node or distant metastasis. The 1-yr risk of progression was 6.5% (95% confidence interval [CI] 5.2-8.0) for patients with primary HG/G3 T1 NMIBC who started BCG treatment, and 4.6% (95% CI 3.3-6.4) 1 yr after the first instillation of the second BCG course for patients who received adequate BCG (n = 746). In conclusion, the contemporary risk of progression for patients with HG/G3 T1 NMIBC who receive BCG appears to be low, especially for patients who receive adequate BCG treatment. PATIENT SUMMARY: Our study shows that for patients with a high-grade bladder tumor who received in-bladder BCG (bacillus Calmette-Guérin), the risk of disease progression was 6.5% at 1 yr after their first BCG instillation. For patients who continued with BCG maintenance treatments, the risk of progression was 4.6% after the first BCG maintenance instillation.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Pijpers OM, van Hoogstraten LMC, Remmers S, et al. Risk of progression in patients with primary T1 high grade non-muscle invasive bladder cancer - a contemporary cohort. Eur Urol Oncol. 2024. PMID: 39327188. doi:10.1016/j.euo.2024.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。